NCT06196905 - An Exploratory Study of MT-2990 in Patients With AAV | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

June 24, 2024

Primary Completion Date

February 28, 2026

Study Completion Date

February 28, 2026

Conditions

Antineutrophil Cytoplasmic Antibody (ANCA) -Associated Vasculitis (AAV)

Interventions

DRUG

MT-2990

i.v. infusion

Trial Locations (8)

Hiroshima University Hospital, Hiroshima

Kagawa University Hospital, Kita-gun

Saitama Medical University Hospital, Iruma-gun

Saitama Medical Center, Kawagoe

Juntendo University Hospital, Bunkyo-ku

NHO Tokyo Medical Center, Meguro-ku

Kyorin University Hospital, Mitaka-shi

Keio University Hospital, Shinjuku-ku